Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Gene-replacement therapy shows promise in X-linked myotubular myopathy

Key clinical point: AT132 decreases ventilator dependence and may improve neuromuscular function in children with X-linked myotubular myopathy.

Major finding: All six patients who received the low dose and one of 10 patients who received the high dose achieved ventilator independence.

Study details: A randomized, delayed treatment–controlled phase 1/2 trial of AT132 in 23 patients with X-linked myotubular myopathy.

Disclosures: Audentes Therapeutics funded the study. Dr. Kuntz had no conflicts of interest.


Bönnemann CG et al. CNS-ICNA 2020, Abstract P.62.